Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Lommatzsch

Pulmonary Disease Denver, CO Medical Doctor

NPI 1750309571 CMS profile 498843

1400 Jackson St, Denver, CO 80206

Open in the dashboard

General payments

$6,257

44 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$31,729 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Steven Lommatzsch of Denver, CO is reported in the CMS Open Payments database as having received $6,257 across 44 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $31,729 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 71st percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,650 10
2023 General $139 2
2022 General $457 9
2021 General $438 6
2020 General $215 7
2019 General $358 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Lommatzsch
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Steven Lommatzsch were reported at $4,650. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Steven Lommatzsch Pulmonary Disease median Middle half National median
2019 $358 $377 $109–$1,340 $163
2020 $215 $230 $56–$907 $114
2021 $438 $269 $68–$1,072 $132
2022 $457 $390 $100–$1,457 $149
2023 $139 $419 $114–$1,659 $160
2024 $0 $476 $123–$1,818 $164
2025 $4,650 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Mannkind Corporation $4,073 3 payments
  2. Insmed, Inc. $525 5 payments
  3. GlaxoSmithKline, LLC. $437 10 payments
  4. AbbVie, Inc. $295 4 payments
  5. Pharming Healthcare, Inc. $247 2 payments
  6. Genentech USA, Inc. $196 5 payments
  7. AstraZeneca Pharmaceuticals LP $142 2 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $110 1 payment
  9. Allergan Inc. $85 6 payments
  10. Pulmonx Corporation $78 1 payment
  11. Other $69 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,500 1 payment
  2. Food and Beverage $2,178 40 payments
  3. Travel and Lodging $548 1 payment
  4. Education $31 2 payments
Products named General payments · program years 2019–2025
  1. AFREZZA $4,073 3 payments
  2. TRELEGY ELLIPTA $244 2 payments
  3. Arikayce $207 2 payments
  4. Xolair $196 5 payments
  5. NUCALA $138 3 payments
  6. AVYCAZ $127 7 payments
  7. FASENRA $125 1 payment
  8. DALVANCE $124 1 payment
  9. JOENJA $122 1 payment
  10. OFEV $110 1 payment
  11. Other $468 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 60 drugs

Part D claims

2,988

Median for Pulmonary Disease: 936

Drug cost

$5,365,217

Median for Pulmonary Disease: $487,987

Branded share of claims

57.8%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trikafta Elexacaftor/Tezacaftor/Ivacaft Brand 124 $3,449,878
Kalydeco Ivacaftor Brand 14 $348,145
Dupixent Pen Dupilumab Brand 57 $214,143
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 151 $184,451
Creon Lipase/Protease/Amylase Brand 34 $176,500
Zemaira Alpha-1-Proteinase Inhibitor Brand 23 $148,792
Fasenra Pen Benralizumab Brand 23 $135,032
Zenpep Lipase/Protease/Amylase Brand 19 $117,620
Spiriva Respimat Tiotropium Bromide Brand 112 $93,796
Spiriva Handihaler Tiotropium Bromide Brand 57 $50,984

The 10 drugs with the highest cost, of 60 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$78,010

Medicare's payments for the services billed

Medicare patients

340

Average age 74

Services billed

850

242 women, 98 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
COPD 75%
High blood pressure 57%
Arthritis 50%
Ischemic heart disease 34%
Osteoporosis 33%
Depression 28%
Atrial fibrillation 19%
Heart failure 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

44 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record